A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

  Subjects -> STATISTICS (Total: 130 journals)
The end of the list has been reached or no journals were found for your choice.
Similar Journals
Journal Cover
Pharmaceutical Statistics
Journal Prestige (SJR): 1.494
Citation Impact (citeScore): 1
Number of Followers: 15  
 
  Hybrid Journal Hybrid journal (It can contain Open Access articles)
ISSN (Print) 1539-1604 - ISSN (Online) 1539-1612
Published by John Wiley and Sons Homepage  [1764 journals]
  • Issue Information

    • Free pre-print version: Loading...

      Abstract: Pharmaceutical Statistics, Volume 21, Issue 6, Page 1111-1113, November/December 2022.
      PubDate: 2022-11-15T04:14:19-08:00
      DOI: 10.1002/pst.2138
      Issue No: Vol. 21, No. 6 (2022)
       
  • Should responder analyses be conducted on continuous outcomes'

    • Free pre-print version: Loading...

      Authors: Robert Abugov; Jennifer Clark, Laura Higginbotham, Feng Li, Lei Nie, David Reasner, Mark Rothmann, Xin Yuan, John Sharretts
      Abstract: Pharmaceutical Statistics, EarlyView.
      PubDate: 2022-11-23T05:40:25-08:00
      DOI: 10.1002/pst.2273
       
  • Sample size re‐estimation in Phase 2 dose‐finding: Conditional power
           versus Bayesian predictive power

    • Free pre-print version: Loading...

      Authors: Qingyang Liu; Guanyu Hu, Binqi Ye, Susan Wang, Yaoshi Wu
      Abstract: Pharmaceutical Statistics, EarlyView.
      PubDate: 2022-11-23T05:24:32-08:00
      DOI: 10.1002/pst.2275
       
  • Statistical modeling approaches for the comparison of dissolution profiles

    • Free pre-print version: Loading...

      Authors: Tony Pourmohamad; Hon Keung Tony Ng
      Abstract: Pharmaceutical Statistics, EarlyView.
      PubDate: 2022-11-20T06:20:09-08:00
      DOI: 10.1002/pst.2274
       
  • AIDE: Adaptive intrapatient dose escalation designs to accelerate Phase I
           clinical trials

    • Free pre-print version: Loading...

      Authors: Yanhong Zhou; Yujie Zhao, Greg Cicconetti, Yunming Mu, Ying Yuan, Li Wang, Sudhir Penugonda, Zeena Salman
      Abstract: Pharmaceutical Statistics, EarlyView.
      PubDate: 2022-11-05T01:19:41-07:00
      DOI: 10.1002/pst.2272
       
  • On the use of extreme value tail modeling for generalized pairwise
           comparisons with censored outcomes

    • Free pre-print version: Loading...

      Authors: Mickaël De Backer; Catherine Legrand, Julien Péron, Alexandre Lambert, Marc Buyse
      Abstract: Pharmaceutical Statistics, EarlyView.
      PubDate: 2022-11-02T02:19:43-07:00
      DOI: 10.1002/pst.2271
       
  • Regional efficacy evaluation in multi‐regional clinical trials using a
           discounting factor weighted Z test

    • Free pre-print version: Loading...

      Authors: Xuanxuan Yu; Lixin Cai, Hao Yu, Zihang Zhong, Min Yang, Jingwei Wu, Jianling Bai
      Abstract: Pharmaceutical Statistics, EarlyView.
      PubDate: 2022-10-31T11:24:33-07:00
      DOI: 10.1002/pst.2270
       
  • Performance of phase‐I dose finding designs with and without a run‐in
           intra‐patient dose escalation stage

    • Free pre-print version: Loading...

      Authors: Jannik Labrenz; Dominic Edelmann, Jonas S. Heitmann, Helmut R. Salih, Annette Kopp‐Schneider, Richard F. Schlenk
      Abstract: Pharmaceutical Statistics, EarlyView.
      PubDate: 2022-10-25T11:09:24-07:00
      DOI: 10.1002/pst.2268
       
  • Statistical considerations for design and analysis of stability,
           comparability and formulation tests

    • Free pre-print version: Loading...

      Authors: Daniel Coleman; Tony Pourmohamad
      Abstract: Pharmaceutical Statistics, EarlyView.
      PubDate: 2022-10-24T03:30:11-07:00
      DOI: 10.1002/pst.2269
       
  • Treatment effect measures under nonproportional hazards

    • Free pre-print version: Loading...

      Authors: Steven Snapinn; Qi Jiang, Chunlei Ke
      Abstract: Pharmaceutical Statistics, EarlyView.
      PubDate: 2022-10-06T11:45:01-07:00
      DOI: 10.1002/pst.2267
       
  • A meta‐analytic framework to adjust for bias in external control
           studies

    • Free pre-print version: Loading...

      Authors: Devin Incerti; Michael T. Bretscher, Ray Lin, Chris Harbron
      Abstract: Pharmaceutical Statistics, EarlyView.
      PubDate: 2022-10-04T03:46:07-07:00
      DOI: 10.1002/pst.2266
       
  • An adaptive biomarker basket design in phase II oncology trials

    • Free pre-print version: Loading...

      Authors: Shufang Liu; Kentaro Takeda, Alan Rong
      Abstract: Pharmaceutical Statistics, EarlyView.
      PubDate: 2022-09-26T08:15:55-07:00
      DOI: 10.1002/pst.2264
       
  • A Bayesian phase I/II design to determine subgroup‐specific optimal dose
           for immunotherapy sequentially combined with radiotherapy

    • Free pre-print version: Loading...

      Authors: Beibei Guo; Yong Zang, Li‐Hsiang Lin, Rui Zhang
      Abstract: Pharmaceutical Statistics, EarlyView.
      PubDate: 2022-09-26T04:45:07-07:00
      DOI: 10.1002/pst.2265
       
  • A comparison of statistical methods for animal oncology studies

    • Free pre-print version: Loading...

      Authors: Tianhui Zhang; Steven J. Novick
      Abstract: Pharmaceutical Statistics, EarlyView.
      PubDate: 2022-08-31T12:35:20-07:00
      DOI: 10.1002/pst.2263
       
  • Should the two‐trial paradigm still be the gold standard in drug
           assessment'

    • Free pre-print version: Loading...

      Authors: Stella Jinran Zhan; Cornelia Ursula Kunz, Nigel Stallard
      Abstract: Pharmaceutical Statistics, EarlyView.
      PubDate: 2022-08-26T10:39:45-07:00
      DOI: 10.1002/pst.2262
       
  • Sensitivity analyses for the principal ignorability assumption using
           multiple imputation

    • Free pre-print version: Loading...

      Authors: Craig Wang; Yufen Zhang, Fabrizia Mealli, Björn Bornkamp
      Abstract: Pharmaceutical Statistics, EarlyView.
      PubDate: 2022-08-23T10:14:52-07:00
      DOI: 10.1002/pst.2260
       
  • A model selection criterion for clustered survival analysis with
           informative cluster size

    • Free pre-print version: Loading...

      Authors: Li‐Chu Chien; Li‐Ying Chang, Chung‐Wei Shen
      Abstract: Pharmaceutical Statistics, EarlyView.
      PubDate: 2022-08-23T04:31:40-07:00
      DOI: 10.1002/pst.2261
       
  • Setting the control limit at release for stability assurance

    • Free pre-print version: Loading...

      Authors: X. Gregory Chen; A. W. Vaart
      Abstract: Pharmaceutical Statistics, EarlyView.
      PubDate: 2022-08-17T10:50:25-07:00
      DOI: 10.1002/pst.2259
       
  • Key considerations for choosing a statistical method to deal with
           incomplete treatment adherence in pragmatic trials

    • Free pre-print version: Loading...

      Authors: Md. Belal Hossain; Mohammad Ehsanul Karim
      Abstract: Pharmaceutical Statistics, EarlyView.
      PubDate: 2022-08-03T03:19:22-07:00
      DOI: 10.1002/pst.2258
       
  • Response to the letter to the editor regarding our article ‘statistical
           methodology for highly variable compounds: A novel design approach for the
           ofatumumab phase 2 bioequivalence study’
           https://doi.org/10.1002/pst.2233

    • Free pre-print version: Loading...

      Authors: Byron Jones; Bingbing Li, Morten Bagger, Alex Goodyear, Inga Ludwig
      Abstract: Pharmaceutical Statistics, EarlyView.
      PubDate: 2022-07-20T05:27:43-07:00
      DOI: 10.1002/pst.2254
       
  • Comments on “Statistical methodology for highly variable compounds: A
           novel design approach for the Ofatumumab phase 2 bioequivalence study”

    • Free pre-print version: Loading...

      Authors: Wanjie Sun; Donald J. Schuirmann, Stella Grosser
      Abstract: Pharmaceutical Statistics, EarlyView.
      PubDate: 2022-07-20T05:17:53-07:00
      DOI: 10.1002/pst.2255
       
  • Evaluating response‐adaptive randomization procedures for recurrent
           events and terminal event data using a composite endpoint

    • Free pre-print version: Loading...

      Authors: Yu‐Lin Mau; Pei‐Fang Su
      Abstract: Pharmaceutical Statistics, EarlyView.
      PubDate: 2022-07-19T06:39:29-07:00
      DOI: 10.1002/pst.2253
       
  • A Bayesian piecewise exponential phase II design for monitoring a
           time‐to‐event endpoint

    • Free pre-print version: Loading...

      Authors: Yun Qing; Peter F. Thall, Ying Yuan
      Abstract: Pharmaceutical Statistics, EarlyView.
      PubDate: 2022-07-18T10:33:46-07:00
      DOI: 10.1002/pst.2256
       
  • Left truncation in linked data: A practical guide to understanding left
           truncation and applying it using SAS and R

    • Free pre-print version: Loading...

      Authors: Yanling Jin; Thanh G. N. Ton, Devin Incerti, Sylvia Hu
      Abstract: Pharmaceutical Statistics, EarlyView.
      PubDate: 2022-07-17T06:40:17-07:00
      DOI: 10.1002/pst.2257
       
  • CUSUMIN: A cumulative sum interval design for cancer phase I dose finding
           studies

    • Free pre-print version: Loading...

      Authors: Tomoyoshi Hatayama; Seiichi Yasui
      Abstract: Pharmaceutical Statistics, EarlyView.
      PubDate: 2022-07-14T06:20:20-07:00
      DOI: 10.1002/pst.2247
       
  • Improving early phase oncology clinical trial design: A case study

    • Free pre-print version: Loading...

      Authors: Alan J. Phillips; Timothy P. Clark
      Abstract: Pharmaceutical Statistics, EarlyView.
      PubDate: 2022-06-29T12:09:37-07:00
      DOI: 10.1002/pst.2252
       
  • Win ratio approach for analyzing composite time‐to‐event endpoint with
           opposite treatment effects in its components

    • Free pre-print version: Loading...

      Authors: Ran Liao; Sujatro Chakladar, Margaret Gamalo
      Abstract: Pharmaceutical Statistics, EarlyView.
      PubDate: 2022-06-29T02:19:24-07:00
      DOI: 10.1002/pst.2248
       
  • Estimators for handling COVID‐19‐related intercurrent events with a
           hypothetical strategy

    • Free pre-print version: Loading...

      Authors: Florian Lasch; Lorenzo Guizzaro
      Abstract: Pharmaceutical Statistics, EarlyView.
      PubDate: 2022-06-28T01:09:11-07:00
      DOI: 10.1002/pst.2244
       
  • Win statistics (win ratio, win odds, and net benefit) can complement one
           another to show the strength of the treatment effect on time‐to‐event
           outcomes

    • Free pre-print version: Loading...

      Authors: Gaohong Dong; Bo Huang, Johan Verbeeck, Ying Cui, James Song, Margaret Gamalo‐Siebers, Duolao Wang, David C. Hoaglin, Yodit Seifu, Tobias Mütze, John Kolassa
      Abstract: Pharmaceutical Statistics, EarlyView.
      PubDate: 2022-06-27T01:24:01-07:00
      DOI: 10.1002/pst.2251
       
  • A semi‐mechanistic dose‐finding design in oncology using
           pharmacokinetic/pharmacodynamic modeling

    • Free pre-print version: Loading...

      Authors: Xiao Su; Yisheng Li, Peter Müller, Chia‐Wei Hsu, Haitao Pan, Kim‐Anh Do
      Abstract: Pharmaceutical Statistics, EarlyView.
      PubDate: 2022-06-24T01:44:37-07:00
      DOI: 10.1002/pst.2249
       
  • A MCP‐Mod approach to designing and analyzing survival trials with
           potential non‐proportional hazards

    • Free pre-print version: Loading...

      Authors: Xiaodong Luo; Yuan Sun, Zhixing Xu
      Abstract: Pharmaceutical Statistics, EarlyView.
      PubDate: 2022-06-23T03:59:52-07:00
      DOI: 10.1002/pst.2241
       
  • Propensity score matching and stratification using multiparty data without
           pooling

    • Free pre-print version: Loading...

      Authors: Jixian Wang; Roland Marion‐Gallois
      Abstract: Pharmaceutical Statistics, EarlyView.
      PubDate: 2022-06-22T10:54:35-07:00
      DOI: 10.1002/pst.2250
       
  • Weighted log‐rank test to compare two survival functions in the presence
           of dependent censoring

    • Free pre-print version: Loading...

      Authors: Philippe Flandre
      Abstract: Pharmaceutical Statistics, EarlyView.
      PubDate: 2022-06-16T04:03:56-07:00
      DOI: 10.1002/pst.2245
       
  • Confirmatory efficacy testing for individual dose–placebo comparisons
           using serial gatekeeping procedure in dose‐finding trials with multiple
           comparison procedures–modeling

    • Free pre-print version: Loading...

      Authors: Yusuke Yamaguchi; Toshifumi Sugitani, Satoshi Yoshida, Kazushi Maruo
      Abstract: Pharmaceutical Statistics, EarlyView.
      PubDate: 2022-06-16T02:54:20-07:00
      DOI: 10.1002/pst.2246
       
  • Optimal unplanned design modification in adaptive two‐stage trials

    • Free pre-print version: Loading...

      Authors: Maximilian Pilz; Carolin Herrmann, Geraldine Rauch, Meinhard Kieser
      Abstract: Pharmaceutical Statistics, EarlyView.
      PubDate: 2022-05-23T09:00:31-07:00
      DOI: 10.1002/pst.2228
       
  • Statistical methodology for highly variable compounds: A novel design
           approach for the Ofatumumab Phase 2 bioequivalence study

    • Free pre-print version: Loading...

      Authors: Byron Jones; Bingbing Li, Morten Bagger, Alex Goodyear, Inga Ludwig
      Abstract: Pharmaceutical Statistics, EarlyView.
      PubDate: 2022-05-23T08:10:16-07:00
      DOI: 10.1002/pst.2233
       
  • Empirical likelihood inference for area under the receiver operating
           characteristic curve using ranked set samples

    • Free pre-print version: Loading...

      Authors: Chul Moon; Xinlei Wang, Johan Lim
      Abstract: Pharmaceutical Statistics, EarlyView.
      PubDate: 2022-05-20T04:28:53-07:00
      DOI: 10.1002/pst.2230
       
  • Standard and reference‐based conditional mean imputation

    • Free pre-print version: Loading...

      Authors: Marcel Wolbers; Alessandro Noci, Paul Delmar, Craig Gower‐Page, Sean Yiu, Jonathan W. Bartlett
      Abstract: Pharmaceutical Statistics, EarlyView.
      PubDate: 2022-05-19T03:28:44-07:00
      DOI: 10.1002/pst.2234
       
  • The utilities and pitfalls of stratified analysis in challenging
           situations

    • Free pre-print version: Loading...

      Authors: Jin Wang
      Abstract: Pharmaceutical Statistics, EarlyView.
      PubDate: 2022-05-16T06:22:53-07:00
      DOI: 10.1002/pst.2232
       
  • 2 stage subgroup‐specific time‐to‐event (2S‐Sub‐TITE): An
           adaptive two‐stage time‐to‐toxicity design for subgroup‐specific
           dose finding in phase I oncology trials

    • Free pre-print version: Loading...

      Authors: Alana McGovern; Andrew G. Chapple, Clement Ma
      Abstract: Pharmaceutical Statistics, EarlyView.
      PubDate: 2022-05-12T11:59:53-07:00
      DOI: 10.1002/pst.2231
       
  • A Bayesian latent class model for predicting gestational age in health
           administrative data

    • Free pre-print version: Loading...

      Authors: Shuang Wang; Gavino Puggioni, Xuerong Wen
      Abstract: Pharmaceutical Statistics, EarlyView.
      PubDate: 2022-05-10T05:00:29-07:00
      DOI: 10.1002/pst.2225
       
  • Doubly‐robust methods for differences in restricted mean lifetimes using
           pseudo‐observations

    • Free pre-print version: Loading...

      Authors: Sangbum Choi; Taehwa Choi, Hye‐Young Lee, Sung Won Han, Dipankar Bandyopadhyay
      Abstract: Pharmaceutical Statistics, EarlyView.
      PubDate: 2022-05-07T02:54:57-07:00
      DOI: 10.1002/pst.2223
       
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
 


Your IP address: 44.200.169.3
 
Home (Search)
API
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-